Company / R&D Expense
Verrica Pharmaceuticals Inc. R&D Expense History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$11.8M
FY2025
5-year range
$4.5M / $15.9M
FY2021-FY2025
Trend
+163.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense returned to growth in FY2025 after 2 years of decline, reaching $12M.
Based on SEC 10-K filings.
$12M in FY2025 with a 3-year CAGR of -9.4%.
Declined from $12M to $12M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -9.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -9.4%, indicating a declining trend.
- In FY2025, r&d expense increased 163.1% year-over-year.
- Peak r&d expense was recorded in FY2022.
- Lowest r&d expense in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -3.86 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.8M | +163.1% |
| FY2024 | $4.5M | -63.1% |
| FY2023 | $12.2M | -23.4% |
| FY2022 | $15.9M | +1.6% |
| FY2021 | $15.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026